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Abstract Dimethyl adipimidate (DMA) reduces K+ loss from,
and dehydration of, red cells containing haemoglobin S (HbS
cells). Three membrane transporters may contribute to these
processes: the deoxygenation-induced cation-selective channel
(Psickle), the Ca2+-activated K+ channel (or Gardos channel) and
the K+-Cl^ cotransporter (KCC). We show that DMA inhibited
all three pathways in deoxygenated HbS cells. The Gardos
channel could be activated following Ca2+ loading. Considerable
KCC activity was present in oxygenated HbS cells, showing a
selective action of DMA on the transporter in deoxygenated
cells. Inhibition of sickling correlated strongly with that of Psickle
and moderately with that of KCC activity. We conclude that
DMA does not inhibit the K+ pathways directly, but acts mainly
by preventing HbS polymerisation and sickling. These findings
are relevant to the development of novel chemotherapeutic agents
for amelioration of sickle cell disease. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Sickle cell disease (SCD) is characterised by anaemia and
vaso-occlusion (reviewed in [1]). These features result from the
presence of haemoglobin S (HbS) rather than the normal
HbA. Abnormal cation transport in red blood cells from
sickle cell patients (termed HbS cells) (reviewed in [2]) is of
particular importance because it leads to solute loss and cell
shrinkage which, in turn, greatly increases the probability of
HbS polymerisation and the sickling shape change [3]. Sickled
HbS cells have a greater rigidity and cytoplasmic viscosity,
resulting in increased microvascular resistance, features which
are central to the pathophysiology of SCD. Three membrane
transporters, which are quiescent in, or absent from, normal
HbA-containing red blood cells (HbA cells), are important in
mediating K loss and cell shrinkage: a deoxygenation-in-
duced non-speci¢c, though cation-selective, channel (termed
Psickle [4]) whose molecular identity remains obscure [5^8] ;
the Gardos channel, a Ca2-activated K channel (probably
IK1) [9^12]; and the K-Cl3 cotransporter or KCC (probably
KCC1) [13^16].
Prevention of cell sickling remains the major ambition of
SCD therapy. A number of reagents have been identi¢ed
which inhibit HbS polymerisation, cell sickling and dehydra-
tion. One such antisickling agent is dimethyl adipimidate
(DMA) [17]. This compound functions as a crosslinking
agent, reacting covalently with available amino groups, par-
ticularly those on lysine residues. It reduces sickling, K loss
and dehydration in deoxygenated HbS cells [17,18] but its
e¡ects on the speci¢c membrane transporters have not been
elucidated.
In this report, we investigated the e¡ects of DMA on the
major passive cation pathways in HbS cells. Results show that
DMA has modest e¡ects on transport in oxygenated HbS
cells. By contrast, in deoxygenated cells, DMA inhibits sick-
ling, Psickle, the Gardos channel and K-Cl3 cotransport,
thereby accounting for its bene¢cial e¡ects on HbS cell vol-
ume. The mechanism of these e¡ects and their signi¢cance are
discussed.
2. Materials and methods
2.1. Chemicals
A23187, clotrimazole and staurosporine were purchased from Cal-
biochem (Nottingham, UK); 86Rb from NEN Du Pont, Stevenage,
UK; and N2 was obtained from BOC (Guildford, UK). All other
reagents came from Sigma Chemical Co., Poole, UK.
2.2. Solutions
The standard MOPS-bu¡ered saline (MBS) comprised (in mM):
145 NaCl, 5 glucose and 10 MOPS (pH 7.4 at 37‡C; 290 þ 5
mOsm/kg). For experiments in which Cl3 dependence of K in£ux
was examined, Cl3 was substituted with NO33 . To investigate the
e¡ects of hypotonic saline, osmolality was adjusted by addition of
distilled water; where required, pH was altered by addition of
HNO3 or NaOH. Stock solutions of ouabain (10 mM) were prepared
in distilled water. Stock solutions of bumetanide (10 mM) and N-
ethylmaleimide (NEM; 100 mM) were made daily in 100 mM Tris
base and distilled water, respectively; those of clotrimazole and stau-
rosporine were prepared in dimethyl sulphoxide and frozen until re-
quired. In all cases, controls and cells treated with inhibitors or other
reagents were exposed to the same concentrations of solvent, whose
¢nal concentrations did not exceed 0.5%.
2.3. Sample collection and handling
Blood samples were obtained with consent and ethical permission
from homozygous HbSS patients, using heparin as anticoagulant.
Cells were washed three times in MBS by centrifugation (2500Ug,
5 min, 4‡C), and the bu¡y coat removed by aspiration. HbS cell
suspensions were then stored on ice until use, within 36 h of collec-
tion.
2.4. Treatment with DMA
DMA solutions (1^10 mM) were made freshly in MBS and titrated
to pH 8. HbS cell samples were suspended in DMA solutions or
control MBS (also adjusted to pH 8 and the same osmolality) at
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4% haematocrit for 30 min at 37‡C, after which they were washed
twice in ice-cold MBS (pH 7.4, 20 times volume of cells) to remove
unreacted DMA.
2.5. Tonometry, O2 saturation and cell shape
After treatment with DMA (or control MBS), red cell suspensions
were incubated at about 40% haematocrit in glass tonometers
(Eschweiler, Kiel, Germany) £ushed with gas mixtures of the appro-
priate O2 tension (air replaced with N2 using a Wo«stho¡ gas mixing
pump), warmed to 37‡C and fully humidi¢ed prior to delivery [19].
Unless indicated otherwise, oxygenated cells refer to those equilibrat-
ed at a PO2 of 150 mm Hg, deoxygenated ones with 0 mm Hg (i.e.
pure N2). Where required, aliquots were removed using a Hamilton
syringe for measurement of O2 saturation (following the method of
Tucker [20]), or ¢xation in glutaraldehyde (MBS plus 1% glutaralde-
hyde, taken to an osmolality of 300 mOsm/kg using distilled water)
for analysis of sickling (using light microscopy and a haemocytome-
ter).
2.6. K+ in£ux
For K in£ux measurements, HbS cell samples were removed from
the tonometers and diluted 10-fold into £ux tubes (¢nal haematocrit
about 4%) also at 37‡C. For measurement of £uxes in experiments
shown in Figs. 2 and 3, cells were exposed to pH 7 and osmolality of
270 mOsm/kg to stimulate the activity of KCC. Ouabain (100 WM)
and bumetanide (10 WM) were always present; A23187 (10 WM), dif-
ferent [Ca2]os (10 WM or 2.5 mM), clotrimazole (10 WM) or EGTA
(100 WM) were added as required. To investigate the e¡ects of NEM
(1 mM) or staurosporine (2 WM), samples were incubated for a further
15 min with these inhibitors before £ux measurement, otherwise it was
determined immediately. 86Rb was used as a tracer for K, added in
150 mM KNO3 solution to give a ¢nal K of 7.5 mM. K in£ux was
measured over a 10 min period after which unincorporated radioiso-
tope was removed by washing in ice-cold isotonic bu¡ered MgCl2
saline (107 mM, pH 7.4). Haematocrit was measured either by the
cyanomethaemoglobin method or by microhaematocrit determina-
tion. In£uxes are expressed as mmol K per litre of cells per hour.
Although this technique measures K in£ux [21], because of the out-
wardly facing electrochemical gradients, the transport pathways
studied will mediate a net K e¥ux. For this reason, the term K
transport (rather than in£ux) is used in much of the following.
2.7. Statistics
Data are presented as mean þ S.D. for n replicates for single experi-
ments representative of at least two others, or as mean þ S.E.M. for n
experiments on samples from di¡erent individuals. Linear regression
(Fig. 3B,C) was calculated using a Sigmaplot program (Jandel Scien-
ti¢c).
3. Results
3.1. E¡ect of DMA on HbS cell shape, O2 saturation and
K+ transport
The relationship between O2 saturation and O2 tension
(PO2 ) is shown in Fig. 1. DMA (5 mM) caused a leftward
shift in the curve with PO2 required for half-maximal O2 sat-
uration being reduced from about 30 to 10 mm Hg, consistent
with a marked increase in O2 a⁄nity. Nevertheless, O2 satu-
ration fell to 0% when cells were incubated in N2 (0 mm Hg
O2) showing that O2 binding was fully reversible. The e¡ect of
DMA (5 mM) on the shape of HbS cells was also assessed
after 15 min incubation in N2. Percentage sickling in fully
deoxygenated control cells was 76 þ 5% (mean þ S.E.M.,
n = 6), declining to 7 þ 3% in DMA-treated cells (91% inhibi-
tion of sickling).
The e¡ect of DMA (5 mM) on K transport was deter-
mined on oxygenated and deoxygenated HbS cells, in the
absence and presence of Cl3 (Fig. 2). DMA had little e¡ect
in oxygenated HbS cells, whilst K transport was markedly
reduced in deoxygenated cells (Fig. 2A). Results are analysed
in more detail in Fig. 2B. The ¢rst two histograms of Fig. 2B
(i and ii) show that DMA inhibited the deoxygenation-in-
duced Cl3-independent K transport (K transport in Cl3-
free medium measured at 150 mm Hg O2 subtracted from that
measured in N2) by 86 þ 4% (mean þ S.E.M., n = 10). Cl3-in-
dependent K £ux could be via either Psickle or the Gardos
channel, activated by Ca2 entry through Psickle. Separate ex-
periments showed that deoxygenation-induced Cl3-independ-
ent K transport was inhibited even in the complete absence
of extracellular Ca2 (nominally Ca2-free plus 100 WM
EGTA) or after the addition of 10 WM clotrimazole (mean
inhibition of 81% by 5 mM DMA). In deoxygenated HbS cells
exposed to high [Ca2]o (2.5 mM) to activate Ca2-dependent
K transport, DMA also inhibited the clotrimazole-sensitive
K £ux (mean inhibition of 88% by 5 mM DMA). These
results imply inhibition of both Psickle and the Gardos channel.
The other four histograms (Fig. 2B, iii^vi) show changes in
the Cl3-dependent K transport (K £uxes in the absence of
Cl3 subtracted from those measured in its presence) in oxy-
genated and deoxygenated HbS cells, usually taken as an in-
dication of the activity of KCC. In air, Cl3-dependent K
transport was similar in magnitude in the presence and ab-
sence of DMA, implying only a modest change in KCC ac-
tivity (16 þ 11% stimulation, mean þ S.E.M., n = 7). Although
Fig. 1. E¡ect of DMA on O2 saturation of HbS cells. HbS cells
(about 40% haematocrit), either untreated or following exposure to
5 mM DMA, were equilibrated for 15 min in tonometers at the O2
tension indicated before aliquots were withdrawn for measurement
of their O2 saturation following the method of Tucker [20]. Single
experiment representative of two others.
Table 1
E¡ect of DMA on the response of KCC in HbS cells to protein ki-
nase (PK) inhibitors
Untreated cells DMA-treated cells
No PK inhibitor 0.19 þ 0.18 0.49 þ 0.11
N-Ethylmaleimide 3.95 þ 0.48 0.95 þ 0.18
Staurosporine 2.02 þ 0.29 1.10 þ 0.16
HbS cells were ¢rst treated with 5 mM DMA. They were then ex-
posed to N-ethylmaleimide (1 mM), staurosporine (2 WM) or no PK
inhibitor for 15 min before measuring Cl3-dependent K £uxes
(mmol/(l cells h)). These were calculated as the di¡erence in K
transport measured in the presence and absence of Cl3, substituted
with NO33 , and were taken as a measure of KCC activity. Data rep-
resent means þ S.E.M. (n = 6).
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the mean change in KCC activity was small, the e¡ect of
DMA was noticeably variable (ranging from a 23% inhibition
to a 64% stimulation). In N2, by contrast, Cl3-dependent K
transport was consistently and markedly inhibited (by
77 þ 8%, mean þ S.E.M., n = 10), indicating substantial inhibi-
tion of KCC in deoxygenated HbS cells (Fig. 2B, v and vi).
3.2. E¡ect of DMA on Psickle and Ca2
+-dependent K+ transport
Activation of the deoxygenation-induced pathway, Psickle, is
associated with HbS polymerisation and cell sickling. The
Gardos channel is activated stochastically at low PO2 s follow-
ing Ca2 entry via Psickle [4]. The inhibitory action of DMA
on Cl3-independent K transport could therefore be ex-
plained either through e¡ects on HbS polymerisation and
sickling, or through a direct inhibitory e¡ect on the transport
pathways per se. These two possibilities were addressed in the
following experiments.
Application of A23187 (10 WM) and 10 WM [Ca2]o was
used to elevate intracellular Ca2 in deoxygenated HbS cells
treated with DMA (5 mM). They resulted in a pronounced
activation of K transport (from 1.03 þ 0.10 to 40.28 þ 0.15
mmol/(l cells h)) which was inhibited almost completely (96%)
by addition of clotrimazole (10 WM), an inhibitor of Ca2-
dependent K channels [9,22]. Considerable Gardos channel
activity can therefore be induced in the presence of DMA if
Ca2 entry into the cell is su⁄cient. Fig. 3 shows the e¡ect of
various concentrations of DMA (1^10 mM) on sickling and
Cl3-independent K transport. Increasing [DMA] progres-
sively inhibited both sickling and Cl3-independent K trans-
port by a similar magnitude (Fig. 3A). Sickling and Cl3-in-
dependent K transport were strongly correlated (r2 = 0.92;
Fig. 3B). It is unlikely that a separate action of DMA would
inhibit Psickle directly by the same amount as it reduces HbS
polymerisation. Taken together, these ¢ndings imply that
DMA inhibits polymerisation and shape change, that this in-
hibits the development of Psickle and that decreased Ca2 entry
via a reduced Psickle activity, prevents activation of the Gardos
channel.
3.3. E¡ect of DMA on K+-Cl3 cotransport
Fig. 2 shows that treating cells with 5 mM DMA inhibited
KCC activity only in deoxygenated HbS cells, but not in oxy-
genated cells, which suggests an inhibitory e¡ect on a control
pathway rather directly on the cotransporter per se. Regula-
tion of KCC is complicated, with many stimuli acting via a
regulatory phosphorylation cascade involving both serine/
threonine and tyrosine kinases and phosphatases. The com-
bined e¡ect of DMA with modulators of the regulatory phos-
phorylation cascade was therefore examined.
The e¡ect of two protein kinase inhibitors, NEM (1 mM)
and staurosporine (2 WM), is shown in Table 1. These reagents
stimulated KCC activity in both untreated and DMA-treated
deoxygenated HbS cells, showing that the cotransporter could
be activated pharmacologically in both cases. Stimulation in
the absence of DMA was consistently higher, being about
two-fold greater for staurosporine, and four-fold for NEM,
compared with DMA-treated cells. Conversely, KCC activity
was modestly increased by DMA treatment in unstimulated
deoxygenated HbS cells (pH 7.4, isotonic MBS, in the absence
of kinase inhibitors, Table 1). Finally, we investigated the
e¡ects of various concentrations of DMA (0^5 mM) on
Cl3-dependent K transport in deoxygenated HbS cells
(Fig. 3A,C). As for Cl3-independent K transport, increasing
[DMA] progressively inhibited KCC. Again, however, e¡ects
varied between experiments and the correlation between cell
sickling and KCC activity was weaker (r2 = 0.64; Fig. 3C)
than that observed for Psickle.
4. Discussion
In this study, we have investigated the mechanism by which
DMA protects HbS cells against K loss and sickling. We
show that DMA inhibited all three pathways for K loss in
deoxygenated cells : Psickle, the Gardos channel and KCC.
Findings are consistent with the main e¡ect of DMA being
Fig. 2. E¡ect of DMA on K transport in HbS cells. HbS cells
(about 40% haematocrit), either untreated or following exposure to
5 mM DMA, were equilibrated for 15 min in tonometers at 150 or
0 mm Hg O2 tension (labelled O2 or N2, respectively) before dilu-
tion 10-fold into £ux tubes for measurement of K in£ux (mmol/-
(l cells h)) at this same O2 tension. A: In£uxes measured in the
presence or absence of Cl3 (substituted with NO33 ). B: K
 in£ux
through the di¡erent K pathways: (i) and (ii) show Psickle/IK1 (de-
oxygenation-induced transport in the absence of Cl3, calculated as
the di¡erence in in£ux in deoxygenated and oxygenated samples in
Cl3-free medium); (iii)^(vi) show KCC activity (Cl3-dependent K
transport, calculated as the di¡erence in in£ux þ Cl3) in oxygenated
(iii and iv) or deoxygenated (v and vi) cells. Histograms represent
means þ S.E.M. for 8 (KCC) or 10 (Psickle) experiments on cells
from di¡erent patients.
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via inhibition of polymerisation and sickling, rather than a
direct e¡ect on the transport pathways per se.
In the 1970s and 1980s, a number of crosslinking reagents
on HbS cells, including DMA, were shown to decrease sick-
ling and K loss from deoxygenated HbS cells [17,18,23]. We
show that DMA had only a modest e¡ect on oxygenated HbS
cells. By contrast, it caused a pronounced reduction in K
transport in deoxygenated cells through inhibition of both
Psickle and the Gardos channel. A substantial clotrimazole-
sensitive, Cl3-independent K transport could be activated
in DMA-treated HbS cells, loaded with Ca2 using the ion-
ophore A23187. Thus the Gardos channel can function in
DMA-treated cells provided Ca2 entry is su⁄cient, and a
direct inhibitory e¡ect of DMA on this transporter is there-
fore unlikely. We also found that Cl3-independent K trans-
port correlated with sickling (r2 = 0.92). These ¢ndings are
consistent with a primary action of DMA to inhibit sickling,
probably through e¡ects on HbS polymerisation, inhibiting
Psickle and Ca2 entry, and hence subsequent activation of
the Gardos channel.
The interaction of DMA with KCC is more complicated.
The cotransporter is a¡ected by many stimuli including cell
swelling, H ions, urea and PO2 [24,25], involving a cascade of
protein kinase and phosphatase enzymes, of both the serine-
threonine and tyrosine types [26,27]. In red cells from many
vertebrates (including human HbA cells), the cotransporter is
O2-dependent [25,28]. In HbS cells, however, the O2 depen-
dence is abnormal [28] and the cotransporter remains active
even in the absence of O2. Because many of the stimuli for
KCC occur in relatively hypoxic areas of the circulation (H
ions in active muscle beds, urea in the renal medulla), the
abnormal O2 dependence may increase the contribution of
KCC to cell dehydration in vivo. The most important action
of DMA on KCC activity was substantial inhibition, but only
in deoxygenated HbS cells, in which KCC was inhibited to
about the same extent as Cl3-independent K transport
(about 80% at 5 mM). By contrast, DMA had little e¡ect
on KCC activity in oxygenated HbS cells. Other inhibitors
of KCC (for example the protein phosphatase inhibitor caly-
culin A [29], or DIOA [30,31]) are not selective for deoxygen-
ated cells and, because the cotransporter is widely expressed in
other tissues, their use in vivo is limited. The mechanism by
which DMA has this selective e¡ect is uncertain. Compared
with Psickle, there was only a moderate correlation between
sickling and KCC activity. In addition, the e¡ects of combi-
nations of DMA and protein kinase inhibitors (NEM and
staurosporine) showed that KCC activity was stimulated by
these reagents in DMA-treated cells, but to a lesser extent
than in the absence of DMA. The interpretation of these
¢ndings is obfuscated by the complexity of KCC control.
They imply an action not solely on HbS polymerisation,
and suggest an inhibitory e¡ect of DMA on the regulatory
phosphorylation pathway.
Oxidative damage may be important in HbS cells. The rel-
ative instability of HbS compared to HbA results in increased
generation of free radicals. Levels of both total and reduced
glutathione are low, the pentose phosphate pathway is im-
Fig. 3. E¡ect of di¡erent concentrations of DMA on sickling and
K transport in HbS cells. HbS cells were exposed to the concentra-
tion of DMA indicated (0^10 mM) and then equilibrated for 15 min
(about 40% haematocrit) in tonometers at 0 mm Hg O2 tension.
Aliquots were then taken for analysis of cell shape or measurement
of K in£ux. Saline for cell ¢xation and £ux measurement were
also equilibrated at 0 mm Hg O2 tension. A: Percentage sickling or
K transport (Psickle/IK1 and KCC calculated as described in legend
to Fig. 2) relative to those values observed in the absence of DMA
(means for three separate experiments). B: Correlation of percentage
sickling and Psickle/IK1, plot calculated by linear regression,
r2 = 0.92. C: Correlation of percentage sickling and KCC, plot cal-
culated by linear regression, r2 = 0.64).
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paired, and oxidative damage is present in both proteins and
lipids. There is evidence that these changes contribute to the
abnormal cation permeability of HbS cells [2,32,33]. Our ¢nd-
ings suggest that, if this is the case, these defects must be
corrected by DMA treatment, or at least remain cryptic under
the conditions of our experiments.
Besides crosslinking reagents like DMA, other approaches
have also been used to ameliorate the e¡ects of SCD. Con-
siderable work has been undertaken to identify e¡ective and
selective inhibitors of the transport pathways responsible for
solute loss. Gardos channel inhibitors include imidazole de-
rivatives such as clotrimazole [9,22,34]. KCC can be inhibited
by intracellular Mg2 [35] (in cells loaded either pharmaco-
logically or via long-term oral supplementation with Mg2
[36,37]), and also by bumetanide analogues and alkanoic
acid derivatives [30,31]. Less directly, antioxidants (such as
N-acetylcysteine) have been used to inhibit oxidant damage
and, under certain conditions, protect against activation of the
Gardos channel (e.g. [38]). Finally, other classes of antisick-
ling agents include substituted benzaldehydes [39], designed to
reduce HbS polymerisation through increasing its O2 a⁄nity.
A number of these approaches have proved e¡ective in vitro,
and in vivo in transgenic mouse models of SCD [36,40]. Some
have also been used in clinical trials [37,41]. To date, however,
no method is adequate for clinical use. It is therefore impor-
tant to understand as fully as possible the pathways which
mediate dehydration and how to inhibit them. The unique
action of DMA, in inhibiting KCC in deoxygenated cells,
may suggest future strategies for treatment of SCD.
In conclusion, we have shown that DMA reduces K trans-
port through all three of the pathways concerned with K loss
(Psickle, the Gardos channel and KCC). A major part of its
action is due to inhibition of cell sickling. Further work to
identify its precise target may be important in the develop-
ment of future chemotherapy for SCD.
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